retatrutide mechanism gip glp-1 glucagon triple agonist Schematic illustration of monoagonists, dual agonists and retatrutide mechanism triple agonist glp-1

Pooled data from these three trials showed that rates of HF hospitalization were not significantly different between DPP-4i and placebo, suggesting that the effect may not be a class effect [100, 101]

Order laboratory tests : Such as blood sugar levels, kidney and liver function tests, and possibly thyroid function

Results: GLP-1RA therapy was associated with lower risks of aortic rupture/dissection requiring surgical repair (hazard ratio [HR] 0.75, 95% CI 0.60 0.94

62 Table 4

As a result, GLP- 1's primary effects include decreasing body weight, protecting against cardiovascular disease, and lowering fasting and postprandial blood glucose levelsall of which are therapeutic targets in T2DM